Transaction DateRecipientSharesTypePriceValue
28th September 2020Susan G. Kim150,000Grant/award etc.$0.00
15th September 2020Christian O Henry750,000Grant/award etc.$0.00
25th August 2020Michael Hunkapiller228,632Open or private sale$6.44$1,472,618.71
24th August 2020John F Milligan25,000Exercise of derivative$3.81$95,250.00
24th August 2020John F Milligan25,000Exercise of derivative$4.45$111,250.00
24th August 2020John F Milligan35,000Exercise of derivative$2.67$93,450.00
24th August 2020John F Milligan25,000Exercise of derivative$2.61$65,250.00
24th August 2020Michael Hunkapiller259,164Open or private sale$6.63$1,719,475.39
21st August 2020Michael Hunkapiller189,847Open or private sale$6.57$1,246,915.10
20th August 2020Michael Hunkapiller256,554Open or private sale$6.47$1,659,801.76
Pacific Biosciences Of California
Pacific Biosciences Of California logo

Pacific Biosciences of California, Inc. engages in the development, manufacture and sale of an integrated platform for genetic analysis. Its products and services include PacBio sequel system, consumables, analytical software, and single molecule real-time (SMRT) compatible products. The company operates through the following geographical segments: North America, Europe, and Asia Pacific.

Ticker: PACB
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1299130
Employees: 404
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Cash at Carrying Value: $69 M (0%)
Inventory, Net: $16 M (0%)
Assets, Current: $170 M (109%)
Property, Plant and Equipment, Net: $29 M (-3%)
Other Assets, Noncurrent: $40 Th (-4%)
Assets: $235 M (58%)
Accounts Payable, Current: $4 M (-49%)
Accrued Liabilities, Current: $18 M (35%)
Liabilities, Current: $132 M (168%)
Liabilities: $174 M (87%)
Common Stock, Value, Issued: $154 Th (0%)
Common Stock, Shares, Issued: $154 Th (0%)
Retained Earnings (Accumulated Deficit): $1 B (0%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $30 Th (500%)
Stockholders' Equity (Parent): $60 M (0%)
Liabilities and Equity: $235 M (58%)
Revenue: $16 M (0%)
Cost of Revenue: $8 M (-28%)
Gross Margin: $7 M (46%)
Research and Development: $15 M (-1%)
Operating Income/Loss: $33 M (8%)
EPS (basic): $0.01 (0%)
EPS (diluted): $0.01 (0%)